

STYLAGE®  
IPN - Like TECHNOLOGY

Bi-SOFT®  
INJECTION TECHNOLOGY

TECHNOLOGY ON THE MOVE

NEW

Enhance  
**THE BEAUTY**  
of your  
**PATIENTS' LIPS.**



SPECIAL  
**LIPS**  
MEPIVACAINE

An **INNOVATIVE** and **PATENTED** formulation<sup>1</sup>.

טל: 03-7589090  
[www.omegamedix.co.il](http://www.omegamedix.co.il)

משווק בלעדית ע"י אומגהמדיקס בע"מ  
רח' בזל 25 | ת.ד. 10256 | פ"ת 4900202

  
OMEGAMEDIX  
THE BEAUTY OF MEDICINE

  
VIVACY®  
PARIS


# VASCULAR PROPERTIES OF THE MEPIVACAINE

The pharmacodynamics features and efficiency of these two molecules are on the whole comparable, as it has been proven in the clinical study mentioned on the following page<sup>6</sup>.

Moreover, literature also states that **mepivacaine does not induce the vasodilatory effects of lidocaine**<sup>4</sup>.

In addition, a study of 23 healthy volunteers who received mepivacaine by intradermal injection **highlighted a vasoconstrictor effect** with concentrations less than and equal to 0.3%<sup>5</sup>.

Mepivacaine is similar to lidocaine in terms of anesthetic efficacy and safety. These two anesthetics are also comparable for their onset time (less than 5 minutes) as well as for their duration (approximately 1 hour 30 minutes)<sup>3</sup>.



1. Granted International Patent WO/2015/097261. Hyaluronic acid compositions including mepivacaine.

3. Tomin, J. & Al. Differences in local anesthetic effects of optically active isomers of local anesthetic compounds. Biotechnol. & Biotechnol. Eq. 20, 9-14. 2006.

4. Lindorf, H.H. « Investigation of the vascular effect of newer local anaesthetics and vasoconstrictors ». Oral Surg., 1979.

5. Fairley, J. W. and Reynolds, F. « An intradermal study of the local anaesthetic and vascular effects of the isomers of mepivacaine ». Br. J. Anaesth., 1981.

6. A non-inferiority, prospective, randomised, double-blind intra-individual clinical study. Main objective: to evaluate the injection comfort of STYLAGE® dermal fillers with mepivacaine versus STYLAGE® with lidocaine in 2 areas: nasogenian folds (65 patients injected with STYLAGE® M mepivacaine versus STYLAGE® M lidocaine) and lips (41 patients injected with STYLAGE® S mepivacaine versus STYLAGE® S lidocaine). Follow-up at 1, 3, 7 days, 1 month, 3 months and 12 months after injection.

